![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Metrochem API Private Limited](https://www.pharmacompass.com/image/flap/metrochem-desktop-header-w24-1gif-62145.gif)
![Metrochem API Private Limited](https://www.pharmacompass.com/image/flap/metrochem-mobgif-80388.gif)
Active Filter(s):
Details:
Present study attests to previous report that Uttroside-B is pharmacologically safe up to five times IC50 dose in acute and sub-chronic toxicity models, while even IC50 dose of sorafenib is toxic to immunocompromised mice, and elevated doses of sorafenib adverse effects.
Lead Product(s): Uttroside B
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Oklahoma Medical Research Foundation
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 26, 2022
Details:
In the initial Scientific Reports study, researchers showed that in animal models, Uttroside-B was ten times more cytotoxic to the HepG2 liver cancer cell line than sorafenib, the only drug approved by the FDA for liver cancer approved at the time.
Lead Product(s): Uttroside B
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 16, 2022
Details:
The patent titled “Uttroside-B and Derivatives Thereof as Therapeutics for Hepatocellular Carcinoma” is a Method Of Use patent that covers the use of Uttroside-B for the treatment of hepatocellular carcinoma (HCC).
Lead Product(s): Uttroside B
Therapeutic Area: Oncology Product Name: Uttroside-B
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 26, 2021